vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $15.7M, roughly 1.3× CF BANKSHARES INC.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -20.4%, a 60.5% gap on every dollar of revenue. On growth, CF BANKSHARES INC. posted the faster year-over-year revenue change (12.6% vs 6.9%). CF BANKSHARES INC. produced more free cash flow last quarter ($18.2M vs $-2.0M). Over the past eight quarters, CF BANKSHARES INC.'s revenue compounded faster (13.7% CAGR vs 2.9%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CFBK vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $20.4M |
| Net Profit | $5.7M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 43.4% | -18.0% |
| Net Margin | 40.0% | -20.4% |
| Revenue YoY | 12.6% | 6.9% |
| Net Profit YoY | 29.9% | 64.9% |
| EPS (diluted) | $0.88 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $20.4M | ||
| Q3 25 | $15.5M | $19.9M | ||
| Q2 25 | $15.6M | $19.6M | ||
| Q1 25 | $14.1M | $17.5M | ||
| Q4 24 | $14.0M | $19.1M | ||
| Q3 24 | $13.1M | $20.2M | ||
| Q2 24 | $12.6M | $21.4M | ||
| Q1 24 | $12.2M | $19.3M |
| Q4 25 | $5.7M | $-4.2M | ||
| Q3 25 | $2.3M | $-8.2M | ||
| Q2 25 | $5.0M | $-11.9M | ||
| Q1 25 | $4.4M | $-14.2M | ||
| Q4 24 | $4.4M | $-11.8M | ||
| Q3 24 | $4.2M | $-11.1M | ||
| Q2 24 | $1.7M | $-12.3M | ||
| Q1 24 | $3.1M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 43.4% | -18.0% | ||
| Q3 25 | 17.5% | -39.7% | ||
| Q2 25 | 41.1% | -59.6% | ||
| Q1 25 | 39.5% | -79.2% | ||
| Q4 24 | 36.9% | -62.5% | ||
| Q3 24 | 40.4% | -55.7% | ||
| Q2 24 | 15.4% | -59.2% | ||
| Q1 24 | 30.9% | -76.4% |
| Q4 25 | 40.0% | -20.4% | ||
| Q3 25 | 15.1% | -41.0% | ||
| Q2 25 | 32.3% | -61.0% | ||
| Q1 25 | 31.4% | -80.8% | ||
| Q4 24 | 35.2% | -62.1% | ||
| Q3 24 | 32.2% | -54.9% | ||
| Q2 24 | 13.5% | -57.7% | ||
| Q1 24 | 25.2% | -84.4% |
| Q4 25 | $0.88 | $-0.07 | ||
| Q3 25 | $0.36 | $-0.16 | ||
| Q2 25 | $0.77 | $-0.23 | ||
| Q1 25 | $0.68 | $-0.28 | ||
| Q4 24 | $0.68 | $-0.23 | ||
| Q3 24 | $0.65 | $-0.22 | ||
| Q2 24 | $0.26 | $-0.25 | ||
| Q1 24 | $0.47 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $184.4M | $63.9M |
| Total Assets | $2.1B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $92.0M | ||
| Q3 25 | $272.4M | $92.4M | ||
| Q2 25 | $275.7M | $101.5M | ||
| Q1 25 | $241.0M | $108.8M | ||
| Q4 24 | $235.3M | $120.4M | ||
| Q3 24 | $233.5M | $118.6M | ||
| Q2 24 | $241.8M | $118.2M | ||
| Q1 24 | $236.9M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $184.4M | $63.9M | ||
| Q3 25 | $179.3M | $64.3M | ||
| Q2 25 | $177.0M | $70.0M | ||
| Q1 25 | $172.7M | $77.6M | ||
| Q4 24 | $168.4M | $87.5M | ||
| Q3 24 | $164.0M | $95.0M | ||
| Q2 24 | $159.6M | $101.6M | ||
| Q1 24 | $158.0M | $109.2M |
| Q4 25 | $2.1B | $115.3M | ||
| Q3 25 | $2.1B | $116.3M | ||
| Q2 25 | $2.1B | $122.0M | ||
| Q1 25 | $2.1B | $129.7M | ||
| Q4 24 | $2.1B | $142.8M | ||
| Q3 24 | $2.1B | $143.6M | ||
| Q2 24 | $2.0B | $149.7M | ||
| Q1 24 | $2.0B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-1.8M |
| Free Cash FlowOCF − Capex | $18.2M | $-2.0M |
| FCF MarginFCF / Revenue | 115.6% | -9.7% |
| Capex IntensityCapex / Revenue | 3.1% | 0.8% |
| Cash ConversionOCF / Net Profit | 3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-1.8M | ||
| Q3 25 | $5.5M | $-8.7M | ||
| Q2 25 | $8.0M | $-7.5M | ||
| Q1 25 | $2.2M | $-11.6M | ||
| Q4 24 | $14.2M | $-3.5M | ||
| Q3 24 | $-1.3M | $362.0K | ||
| Q2 24 | $4.0M | $-9.5M | ||
| Q1 24 | $-1.2M | $-9.8M |
| Q4 25 | $18.2M | $-2.0M | ||
| Q3 25 | $5.2M | $-8.9M | ||
| Q2 25 | $7.8M | $-7.8M | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $13.9M | $-3.6M | ||
| Q3 24 | $-1.3M | $311.0K | ||
| Q2 24 | $4.0M | $-9.5M | ||
| Q1 24 | $-1.2M | $-9.9M |
| Q4 25 | 115.6% | -9.7% | ||
| Q3 25 | 33.6% | -44.7% | ||
| Q2 25 | 50.3% | -39.6% | ||
| Q1 25 | 15.2% | — | ||
| Q4 24 | 99.6% | -18.9% | ||
| Q3 24 | -9.9% | 1.5% | ||
| Q2 24 | 31.6% | -44.7% | ||
| Q1 24 | -9.5% | -51.4% |
| Q4 25 | 3.1% | 0.8% | ||
| Q3 25 | 1.7% | 0.9% | ||
| Q2 25 | 0.7% | 1.1% | ||
| Q1 25 | 0.4% | 0.0% | ||
| Q4 24 | 1.9% | 0.7% | ||
| Q3 24 | 0.2% | 0.3% | ||
| Q2 24 | 0.1% | 0.4% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
